See the latest technology and patient care services in a real-life setting at innovatED.
Somebody has to take charge, lead, come up with something new. Where is that person? You can find several of the trailblazers in the Exhibit Hall at innovatED. This space features products and services vetted by a team of emergency physicians and showcased working together in a true-to-life environment. Engage in dialogue with the companies and experience the current thinking, departmental design solutions, cutting-edge products and services, and best practices driving change in the ED. This experience is particularly valuable for those looking to rebuild their emergency medicine services or bring their facility up to speed on new technologies.
Who’s driving change in EM? The people and companies listed here.
Presenting Supporters
Janssen Pharmaceutical Companies of Johnson & Johnson
www.janssenpharmaceuticalsinc.com
As a member of the Janssen Pharmaceutical Companies, Janssen Pharmaceuticals, Inc., is dedicated to addressing and resolving the major unmet medical needs of our time. Driven by our commitment to patients, health care professionals, and caregivers, we strive to develop sustainable and integrated health care solutions by working in partnership with all stakeholders on the basis of trust and transparency. Our daily work is guided by meeting goals of excellence in quality, innovation, safety, and efficacy in order to advance patient care.
Durata Therapeutics
www.duratatherapeutics.com
Durata Therapeutics, Inc. is an innovative new pharmaceutical company focused on the development and commercialization of differentiated therapeutic solutions for physicians and other providers to advance patient care in infectious disease and acute illnesses.
Durata’s lead product, DALVANCE (dalbavancin) for injection, was approved by the U.S. Food and Drug Administration (FDA) on May 23, 2014, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI). It was the first drug approved as a qualified infectious disease product, and became available for order on July 18, 2014.
“DALVANCE’s unique dosing regimen offers a new alternative for the treatment of serious skin infections by allowing patients, healthcare professionals, and hospitals to move beyond the standard daily or twice-daily IV antibiotic infusions,” said Paul R. Edick, Durata’s CEO. “We are very pleased that DALVANCE is now available to millions of Americans who may benefit from this innovative treatment option for ABSSSI.”
Important Safety Information
Contraindications: DALVANCE is contraindicated in patients with known hypersensitivity to dalbavancin.
Warnings and Precautions: Serious hypersensitivity (anaphylactic) and skin reactions have been reported with glycopeptide antibacterial agents, including DALVANCE; exercise caution in patients with known hypersensitivity to glycopeptides.
Rapid intravenous infusion of glycopeptide antibacterial agents can cause reactions, including flushing of the upper body, urticaria, pruritus, and rash.
ALT elevations with DALVANCE treatment were reported in clinical trials.
Clostridium difficile-associated diarrhea (CDAD) has been reported with nearly all systemic antibacterial agents, including DALVANCE. Evaluate if diarrhea occurs.
Adverse Reactions: The most common adverse reactions in patients treated with DALVANCE in Phase 2/3 clinical trials were nausea (5.5 percent), headache (4.7 percent), and diarrhea (4.4 percent).
Use in Specific Populations: In patients with renal impairment whose known creatinine clearance is less than 30 mL/min and who are not receiving regularly scheduled hemodialysis, the recommended two-dose regimen for DALVANCE is 750 mg followed one week later by 375 mg. No dosage adjustment is recommended for patients receiving regularly scheduled hemodialysis, and DALVANCE can be administered without regard to the timing of hemodialysis.
For more information about DALVANCE and for full prescribing information, visit www.dalvance.com.
Diamond Supporters
Covidien
www.covidien.com
Covidien is a leading global health care company innovating medical solutions focused on patient outcomes. Our comprehensive technologies for emergency medicine include intubated and nonintubated capnography, pulse oximetry, noninvasive positive pressure ventilation, airway accessories, and wound management supplies. Covidien Neurovascular offers technologies for specialists treating ischemic and hemorrhagic stroke, including stentrievers, embolization coils, and flow diversion. Covidien is committed to providing clinicians the latest technology to treat patients. Please visit www.covidien.com to learn more about our businesses.
“Reducing disability and mortality for acute ischemic stroke is dependent upon rapid neurologic assessment by the emergency room physician and fast treatment to reverse ischemia to reperfuse at-risk brain tissue.”.”
—Sam O. Zaidat, MD, MS, FAAN, FAHA, professor of neurology, neurosurgery, and radiology; director, Comprehensive Stroke Center; and chief, neuro-interventional division, Medical College of Wisconsin/Froedtert Hospital, Milwaukee
“I know because of what has not happened during the six years of using capnography; we have not only saved money, we’ve saved lives..”
—Ray Maddox, MD, St. Joseph’s/Candler Health System, Savannah, Georgia
HKS, Inc.
innovatED Designer
www.hksinc.com
For 74 years, HKS has nurtured a culture that reveres both innovation and customer focus. The firm’s experience includes health care, commercial, sports, hospitality, government, aviation, educational, and retail projects. HKS has expanded its specialized health care design services by incorporating HKS Team ED into its offerings. Team ED provides health care clients with a full array of specialized services for emergency department design, including predesign consulting, operational and strategic planning, and simulation modeling.
No Responses to “Who’s Driving Change at innovatED?”